Idoxifene - patents, research & applications

18,892Patents

62Research papers

1,535Patents - last 3 years

0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Merck and Co Inc	2,341
2	Bristol Myers Squibb Co	1,352
3	Merck KGaA	749
4	Roche Holding AG	723
5	AstraZeneca PLC	513

6	AbbVie Inc	505
7	Pfizer Inc	375
8	Organon and Co	312
9	Madrigal Pharmaceuticals Inc	280
10	Daiichi Sankyo Co Ltd	239

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`A61P`	Therapeutic activity (drug indications)	16,944
2	`A61K`	Medicinal preparations	13,915
3	`C07D`	Heterocyclic compounds	9,983
4	`C07K`	Peptides	3,851
5	`C12N`	Microorganisms, enzymes	1,480

6	`G01N`	Investigating / analysing materials	1,451
7	`Y02A`	Climate change adaptation	1,270
8	`C07C`	Acyclic and carbocyclic compounds	1,208
9	`C12Q`	Measuring/testing involving enzymes	740
10	`C07F`	Organometallic compounds	699

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Representative patents

The filings that best characterise the patent activity around this compound, most-referenced first.

Title	Year	Assignee
Method for synthesizing midbody of idoxifene	2026
Compositions of (Z) -idoxifene and methods of enriching same	2024
METHOD OF TREATING POST MENOPAUSAL DISEASES, INCLUDING OSTEOPOROSIS USING IDOXIFENE DERIVATIVES	2000
THERAPEUTIC AGENTS BASED ON IDOXIFENO, USEFUL IN THE TREATMENT OF OSTEOPOROSIS	2000
Route B process for idoxifene	1999

How research activity has moved

Papers published per year for this compound, over the last decade of indexed records.

Year	Papers
2019	1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Michael Jarman	Institute of Cancer Research	13
2	Mitch Dowsett	Royal Marsden Hospital	5
3	R. Charles Coombes	Charing Cross Hospital	5
4	V. Craig Jordan	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	4
5	Maxine Gowen	New Frontier	4

6	Ian R. Hardcastle	Institute of Cancer Research	4
7	Eliot H. Ohlstein	New Frontier	4
8	Tianli Yue	New Frontier	4
9	Jack D. Henion	Cornell University	4
10	Ben P. Haynes	The Honourable Society of Lincoln's Inn	4

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms	2001	99	Endometrial and Cervical Cancer Treatments
Bioanalytical High-Throughput Selected Reaction Monitoring-LC/MS Determination of Selected Estrogen Receptor Modulators in Human Plasma: 2000 Samples/Day	2000	97	Advanced Proteomics Techniques and Applications
High-resolution MRI and micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials: application to calcaneal bone in postmenopausal women after one year of idoxifene treatment	2002	88	Bone health and osteoporosis research
Idoxifene: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats	1998	88	Menopause: Health Impacts and Treatments
Atmospheric pressure photoionization liquid chromatographic–mass spectrometric determination of idoxifene and its metabolites in human plasma	2002	85	Mass Spectrometry Techniques and Applications

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of idoxifene?

Idoxifene has the molecular formula C28H30INO with a molecular weight of 523.4585 g/mol. Its canonical IUPAC name is 1-[2-[4-[(E)-1-(4-iodophenyl)-2-phenylbut-1-enyl]phenoxy]ethyl]pyrrolidine.

Which companies hold the most patents related to idoxifene?

The leading patent assignees in the idoxifene space are Merck and Co Inc with 2341 patents, Bristol Myers Squibb Co with 1352 patents, Merck KGaA with 749 patents, Roche Holding AG with 723 patents, and AstraZeneca PLC with 513 patents.

What research areas are most represented in the patent portfolio for idoxifene?

The patent portfolio is dominated by the CPC subclass A61P (pharmaceutical preparations), which accounts for 16,944 patents, followed by A61K (medicinal preparations) with 13,915 patents, and C07D (heterocyclic compounds) with 9,983 patents.

Who are the most prolific authors publishing on idoxifene?

Michael Jarman from the Institute of Cancer Research is the most prolific author with 13 papers on the compound. Other major contributors include Mitch Dowsett from Royal Marsden Hospital with 5 papers and R. Charles Coombes from Charing Cross Hospital with 5 papers.

What clinical applications have been studied for idoxifene based on the available literature?

Published research on idoxifene covers several clinical areas. One study examined idoxifene as a selective estrogen receptor modulator that prevents bone loss and lowers cholesterol levels in ovariectomized rats while decreasing uterine weight in intact rats. Another study evaluated high-resolution MRI and micro-finite element analysis for measuring changes in bone mechanical properties during clinical trials of idoxifene treatment in postmenopausal women over one year.